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http://dx.dEfficacy of a Viral Load-Based, Risk-Adapted,
Preemptive Treatment Strategy for Prevention of
Cytomegalovirus Disease after Hematopoietic Cell
Transplantation
Margaret L. Green,1,2 Wendy Leisenring,1,3 Daniel Stachel,6 Steven A. Pergam,1,2
Brenda M. Sandmaier,1,2 Anna Wald,1,2,4,5 Lawrence Corey,1,2,4 Michael Boeckh1,2Cytomegalovirus (CMV) surveillance and preemptive therapy is the most commonly used strategy for CMV
disease prevention in hematopoietic cell transplantation recipients. In 2007, we introduced aCMVprevention
strategy for patients at risk for CMV disease using quantitative PCR surveillance, with treatment thresholds
determined by patient risk factors. Patients (N 5 367) received preemptive therapy either at a plasma viral
load of$500 copies/mL, at$100 copies/mL if receiving$1mg/kg of prednisone or anti-T cell therapies, or if
a $5-fold viral load increase from baseline was detected. Compared with patients before 2007 undergoing
antigenemia-based surveillance (n 5 690) with preemptive therapy initiated for any positive level, the risk-
adapted PCR-based strategy resulted in similar use of antiviral agents, and similar risks of CMV disease, tox-
icity, and nonrelapse mortality in multivariable models. The cumulative incidence of CMV disease by day 100
was 5.2% in the PCR group compared with 5.8% in the antigenemia group (1 year: 9.1% PCR vs 9.6% antige-
nemia). Breakthrough CMV disease in the PCR group was predominantly in the gastrointestinal (GI) tract (15
of 19 cases; 79%). However, unlike CMV pneumonia, CMVGI disease was not associated with increased non-
relapse mortality (adjusted hazard ratio, 1.19; P5 .70 [GI disease] vs 8.18; P\.001 [pneumonia]). Thus, the
transition to a preemptive therapy strategy based on CMV viral load and host risk factors successfully pre-
vented CMV diseasewithout increasing the proportion of patients receiving preemptive therapy and attribut-
able toxicity. Breakthrough disease in PCR-based preemptive therapy occurs at a low incidence and presents
primarily as GI disease, which is more likely to be responsive to antiviral therapy.
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However, a significant variation among trans-
plantation centers in testing methods, frequency,
and thresholds for initiating preemptive therapy
remains [3,4]. As of 2003, nearly half of trans-
plantation centers reported using a surveillance
strategy based on pp65 antigen in peripheral blood
leukocytes, whereas the remainder had transitioned
to a strategy based on plasma or whole blood CMV
DNA level measured by PCR [4]. Several cohort stud-
ies [5-12] and a few small randomized clinical trials
[13-15] have compared the performance of these 2
tests for use in a preemptive treatment strategy.
Although pp65 antigenemia testing has been shown
to perform well in CMV disease prevention, several
operational disadvantages limit its use: the test
requires circulating neutrophils and, thus, is not
reliable before engraftment; the samples require
rapid processing to retain sensitivity; and
interpretation of the slides requires highly trained1687
1688 Biol Blood Marrow Transplant 18:1687-1699, 2012M. L. Green et al.personnel and has a high interobserver variability. In
contrast, CMV DNA measurement by real-time
PCR is more sensitive than pp65 antigenemia,
provides more precise quantitation of CMV, can be
automated, and is markedly less affected by specimen
transport conditions and time [7-9].
In 2007, the Fred Hutchinson Cancer Research
Center (FHCRC) changed from a preemptive strategy
based on weekly surveillance of pp65 antigenemia to
one based on CMV DNAemia measured by quantita-
tive real-time PCR for patients at risk for CMV dis-
ease. The strategy was designed with 2 primary
goals: (1) to ascertain a treatment threshold that was
low enough to take advantage of the sensitivity of the
PCR assay to identify early patients most likely to
have a short doubling time [16] and those who progress
to disease without high viral loads [7] and (2) to avoid
increasing the overall proportion of patients treated to
minimize adverse effects of therapy. We thus selected
the viral load thresholds for preemptive treatment
based on the patient’s degree of immunosuppression,
as a factor that correlates with viral replication dynam-
ics [16]. Additionally, rapid relative increases of viral
load were also chosen as an indication for preemptive
treatment. The thresholds were chosen a priori with
the goal of designing a surveillance strategy that could
be implemented and adopted in a large transplantation
center. In this study, we report the efficacy of this risk-
adapted, viral load-based strategy for the prevention of
CMV disease after HCT and identify characteristics
and outcome of breakthrough CMV disease with con-
temporary preemptive strategies.METHODS
Patient Selection
The study included patients of all ages who were at
risk of CMV disease and received their first allogeneic
HCT at the FHCRC between 2002 to 2005 and 2007
to 2009. Patients at risk for CMV disease were either
CMV seropositive (R1; D2 or D1) or seronegative
patients receiving stem cells from seropositive donors
(D1/R2). Patients receiving ex vivo T cell-depleted
stem cell products or umbilical cord blood transplanta-
tions were excluded [17]. We excluded patients who
underwent mixed CMV surveillance—sometimes
tested by antigenemia, other times by PCR, during
the transition period in 2006 and early 2007. During
this time period, there were several ongoing clinical
trials for CMV disease prevention; patients random-
ized to the study drug/vaccine in these studies were
also excluded.
To control for secular trends in the frequency of
secondary neutropenia, Gram-negative bacteremia,
and mortality during the study time period, we also
analyzed patients who were CMV seronegative,received stem cells from a seronegative donor
(D2/R2), and underwent first allogeneic bone mar-
row (BM) or peripheral blood stem cell transplantation
at the FHCRC between 2002 to 2005 and 2007 to
2009. Because these low-risk patients continued to un-
dergo antigenemia-based preemptive therapy, they
were not included in the analysis of CMV disease.
This protocol was approved by the Institutional
Review Board at the FHCRC.
Data Sources
The FHCRC prospectively collects demographic,
clinical, and laboratory data from all patients undergo-
ing HCT and the donors from the pretransplantation
period through at least the first 100 days after trans-
plantation. Clinical and laboratory data after discharge
from the center are also available from the long-term
follow-up database; additional pathology, radiology,
and antiviral therapy data were extracted from the elec-
tronic medical records.
CMV Surveillance, Treatment, and Antiviral
Prophylaxis
Patients at risk for CMV reactivation underwent
weekly surveillance testing either by pp65 antigenemia
or by PCR to measure plasma viral load. During the
antigenemia era, surveillance testing was started after
engraftment (after day 10) and continued weekly until
day 100 [18]. As the PCR test does not require neutro-
phils, weekly surveillance was initiated about day 0.
Patients who received preemptive therapy in the first
100 days or who were receiving steroids for chronic
graft-versus-host disease (cGVHD) continued weekly
PCR surveillance throughout the first year in both pe-
riods. Preemptive therapy with either induction-dose
ganciclovir (5 mg/kg i.v. every 12 hours) or foscarnet
(90 mg/kg every 12 hours; in case of neutropenia) was
initiated for an antigenemia result of $1 positive cell
per 2 slides [18] or, in the PCR era, for a CMV viral
load $500 copies/mL or a 5-fold increase from base-
line within the previous month. Patients receiving
anti-T cell therapies such as alemtuzumab or antithy-
mocyte globulin, or $1mg/kg prednisone equivalent
were treated at a viral load of$100 copies/mL. For pa-
tients with CMV viral loads under the treatment
threshold, twice weekly testing was recommended. In-
duction dosing was continued for at least 7 days at
which point, if antigenemia or plasma CMV viral
load were decreasing, the therapy was changed to
maintenance-dose ganciclovir (5mg/kg i.v. once daily),
which would be continued for at least 2 weeks or until
the repeat test was negative. After day 100, PCR sur-
veillance was recommended in both cohorts with a pre-
emptive treatment threshold of $1,000 copies/mL or
a 5-times increase of viral load within 1 month. CMV
plasma PCR was tested by a double-primer assay as
Biol Blood Marrow Transplant 18:1687-1699, 2012 1689CMV Prevention Strategy among HCT Recipientspreviously described [7]; the assay has a threshold of 50
copies/mL plasma.
Patients with CMV disease were treated with in-
duction dose ganciclovir or foscarnet for 21 days, fol-
lowed by a maintenance dose for at least 3 to 4
weeks, or until day 100. Additionally, patients with
CMV pneumonia were given CMV immunoglobulin
(150 mg/kg) every other day for 14 days, then once
weekly for the duration of maintenance treatment.
Acyclovir (250 mg/m2 i.v. or 800 mg orally twice
daily) or valacyclovir (500 mg orally twice daily) was
given to all patients for HSV-1, HSV-2, and VZV pro-
phylaxis for at least 1 year [19]. No patients received
high-dose acyclovir prophylaxis. All D1/R2 and
D2/R2 patients received either CMV-seronegative
or leukoreduced blood products until November
2009, at which time they received leukoreduced blood
products only.
Other Prophylaxis
Patients received levofloxacin (750 mg once daily)
or similar antibiotics during episodes of chemother-
apy-induced neutropenia, trimethoprim/sulfamethox-
azole or dapsone for Pneumocystis jirovecii prophylaxis
[20] and fluconazole (400 mg once daily) for preven-
tion of Candida infections [21]. Patients with a pre-
transplantation mold infection received an antifungal
agent with mold activity in place of fluconazole. Con-
ditioning regimens and GVHD prophylaxis and treat-
ment were performed according to center protocol, as
described elsewhere [22].
Outcomes and Definitions
The primary outcome of this study was CMV dis-
ease in the first 100 days and 1 year posttransplanta-
tion, which was classified according to standard
definitions [23]. Secondary outcomes included CMV
reactivation defined as any positive surveillance test;
nonrelapse mortality (NRM) at 1-year posttransplan-
tation defined as all deaths not due to morphologic re-
lapse of the underlying disease (in recipients of
nonmyeloablative conditioning, NRM was defined as
all deaths not due to morphologic relapse or progres-
sion of the underlying disease), CMV-related neutro-
penia—either due to direct effects of the virus or to
suppressive effects from treatment—was defined as
an absolute neutrophil count (ANC) of \200/mm3
or\500/mm3 in a patient who had previously achieved
engraftment (ANC.1,000/mm3 for 3 days) within 60
days of initiating CMV therapy. The cultivation of any
Gram-negative bacteria from the blood was consid-
ered an episode of Gram-negative bacteremia. Invasive
fungal disease was classified according to the European
Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and the
National Institute of Allergy and Infectious DiseasesMycoses Study Group (EORTC/MSG) guidelines
[24]; only ‘‘proven’’ and ‘‘probable’’ cases were in-
cluded in these analyses.
Statistical Analysis
Patient characteristics were compared across co-
horts using the c2 test. Univariate and multivariable
competing risk regression models were used to calcu-
late cumulative incidence estimates of outcomes de-
tailed previously [25]. Death was treated as
a competing risk for all nonmortality outcomes. Re-
lapse was treated as a competing risk forNRM. Factors
considered as potential confounders of the relationship
between CMV surveillance and outcome were age, sex,
donor age, sex mismatch, underlying disease risk
(standard or high vs low), CMV serostatus, HSV-1 se-
rostatus, conditioning regimen (myeloablative with
high-dose total body irradiation [TBI], myeloablative
without high-dose TBI, and nonmyeloablative),
HLA matching (matched/related or unrelated/mis-
matched), and stem cell source (BM vs peripheral
blood stem cells). Posttransplantation factors consid-
ered as time-dependent covariates were moderate to
severe acute GVHD (aGVHD; grade 0-1 vs grade 2
or grade 3-4), cGVHD, and secondary neutropenia
(ANC \500 after engraftment) [19,26-28]. All data
were analyzed using Stata v 11.2 (StataCorp, College
Station, TX).
Because the CMV surveillance comparison groups
were collinear with time, we could not determine
whether differences in the incidence of secondary neu-
tropenia or Gram-negative bacteremia that occurred
over the study period were related to the CMV surveil-
lance strategy without introducing a third group of pa-
tients that spanned both eras but did not undergo the
same CMV surveillance strategy. Such a cohort was
represented by the patients who were D2/R2. For
these models, an interaction term between era and
use of surveillance was used to test for the differential
effect on the outcome of each CMV surveillance group
as comparedwithD2/R2 patients within the same era.
All reported P values were 2-sided, calculated from
theWald test, with values of less than .05 considered to
be significant.RESULTS
The 2 CMV surveillance groups included 690 pa-
tients in the antigenemia group and 367 patients in the
PCR group. The groups were similar with respect to
patient age, sex, diagnosis, disease risk, HLA-
matching, sex matching, donor age, and CMV do-
nor/recipient serostatus (Table 1). Compared with
the patients monitored by antigenemia, patients mon-
itored by PCRweremore likely to have received a non-
myeloablative conditioning regimen (P \ .001) and
Table 1. Patient Characteristics
CMV pp65 Antigen CMV DNA PCR CMV D2/R2
2002-2005 2007-2009 2002-2005 2007-2009
(n 5 690) (n 5 367) (n 5 540)
Median (IQR)
Age in years 46.8 (34-56) 51.7 (34-61) 45.7 (29-58)
Donor age in years 40.1 (30-49) 37.2 (26-49) 36.1 (26-47)
n (%)
Male sex 393 (57) 200 (55) 349 (65)
Disease
Acute leukemia 322 (47) 154 (42) 231 (43)
Chronic leukemia 83 (12) 47 (13) 67 (12)
Lymphoma 83 (12) 41 (11) 85 (16)
Other 202 (29) 125 (34) 157 (29)
Disease risk*
Low risk 88 (13) 88 (24) 99 (18)
Standard risk 325 (47) 181 (49) 257 (48)
High risk 277 (40) 98 (27) 184 (34)
HSV-1 serostatus†
Negative 130 (19) 59 (16) 117 (22)
Positive 560 (81) 306 (84) 409 (78)
Conditioning
Myeloablative with high-dose TBI‡ 150 (22) 59 (16) 127 (24)
Myeloablative without high-dose TBI 327 (47) 144 (39) 241 (45)
Nonmyeloablative 213 (31) 164 (45) 172 (32)
HLA matching
Matched/related 337 (49) 163 (44) 204 (38)
Mismatched/unrelated 353 (51) 204 (56) 336 (62)
Stem cell source
BM 125 (18) 97 (26) 109 (20)
Peripheral blood 565 (82) 270 (74) 431 (80)
Sex matching
Matched 364 (53) 195 (53) 300 (56)
Male donor to female recipient 152 (22) 83 (23) 104 (19)
Female donor to male recipient 174 (25) 89 (24) 136 (25)
CMV donor/recipient status
D+/R+ 280 (41) 153 (41) –
D2/R+ 286 (41) 154 (42) –
D+/R2 124 (18) 60 (17) –
D2/R2 – – 540 (100)
GVHD prophylaxis
Calcineurin inhibitor alone 17 (3) 1 (<1) 7 (1)
Calcineurin inhibitor + MMF 228 (33) 106 (29) 166 (31)
Calcineurin inhibitor + MTX 387 (56) 104 (28) 272 (50)
Other§ 58 (8) 156 (43) 95 (18)
GVHD prophylaxis includes sirolumus 15 (2) 10 (3) 22 (4)
Posttransplantation events¶ Cumulative Incidence Estimate (95% CI), No. Events
aGVHD
Grade 2-4 day 100 67.4% (64-71) 465 events 66.9% (62-71) 245 events 69.4% (65-73) 375 events
1 year 68.0% (64-71) 469 events 68.2% (63-73) 250 events 70.0% (66-74) 378 events
Grade 3-4 day 100 13.4% (11-16) 95 events 12.0% (9-16) 44 events 13.5% (11-16) 73 events
1 year 14.3% (11-16) 99 events 12.2% (9-16) 45 events 13.7% (11-17) 74 events
Overall mortality
Day 100 13.8% (11-17) 95 events 10.9% (8-15) 40 events 11.1% (8-13) 55 events
1 year 37.4% (34-41) 258 events 38.3% (33-44) 131 events 24.8% (21-29) 134 events
Morphologic relapse
Day 100 11.9% (10-14) 82 events 13.6% (10-17) 50 events 5.4% (4-7) 29 events
1 year 24.3% (21-28) 168 events 23.6% (19-28) 84 events 13.7% (11-17) 74 events
CMV indicates cytomegalovirus; D2/R2, CMV seronegative donor/CMV seronegative recipient; IQR, interquartile range; TBI, total body irradiation;
BM, bone marrow; D+/R+, CMV seropositive donor/CMV seropositive recipient; D2/R+, CMV seronegative donor/CMV seropositive recipient;
D+/R2, CMV seropositive donor/CMV seronegative recipient; GVHD, graft-versus-host disease; MMF, mycophenolate mofetil; MTX, methotrexate;
aGVHD, acute GVHD; CI, confidence interval.
*Low-risk disease includes chronic lymphocytic leukemia (CLL) in complete remission (CR), low-grade non-Hodgkin lymphoma (NHL), high-grade NHL
in CR, Waldenstrom disease, multiple myeloma (MM) in CR, acute lymphoblastic leukemia (ALL) in first CR, myeloproliferative disease, primary immu-
nodeficiencies, and hemoglobinopathies. Standard risk disease includes refractory anemia (RA/RARS), CLL not in CR, MM not in CR, acute myeloid
leukemia (AML) in CR, and chronic myeloid leukemia (CML) in first chronic phase (CP). High-risk disease includes refractory anemia with excess blasts
(RAEB/RAEB-t), AML evolved from myelodysplastic disease (MDS), high-grade NHL not in CR, Hodgkin disease, secondary MDS, AML not in CR, CML
in second CP or accelerated phase/blast crisis, nonhematologic malignancies, ALL not in first CR [41].
†These data are missing in 2 patients from PCR cohort and 16 patients in D2/R2.
‡High-dose TBI, >12 Gy.
§Other includes regimens such as MMF or MTX alone, regimens using cyclophosphamide, sirolimus, or high-dose steroids.
¶Cumulative incidence estimates for GVHD and relapse were calculated with death as a competing risk.
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receive methotrexate-containing GVHD prophylaxis
(P\ .001).CMV Disease
The incidence of CMVdisease during the first year
after HCT did not differ by surveillance method
(Table 2 and Figure 1C and 1D). The probability of
CMV disease among seropositive patients (R1) was
12.9% in the antigenemia group and 11.5% in the
PCR group. There were only 5 cases of CMV disease
in the D1/R2 population (cumulative incidence 2.7%
antigenemia vs 3.5% PCR). HLA mismatch or unre-
lated donor was associated with increased risk of
CMV disease, whereas the use of either a nonmyeloa-
blative conditioning regimen or myeloablative without
high-dose TBI were associated with a decreased prob-
ability of CMV disease (Table 3). After adjusting for
both of these factors, aGVHD grades 3 to 4 and
cGVHD also remained significantly associated with
CMV disease.
Despite the absence of a significant difference in
CMV disease overall with the PCR-based surveillance
strategy, the PCR-based surveillance strategy ap-
peared associated with a lower risk of CMV pneumo-
nitis (adjusted hazard ratio [HR], 0.55; 95%
confidence interval [CI], 0.3-1.1; P 5 .07) but with
a trend toward increased risk of gastrointestinal (GI)
disease (aHR 1.41; 95% CI, 0.8-2.6; P 5 .27) after
adjusting for conditioning regimen, recipient CMV
serostatus, and HLA matching.
Although the prevention of CMVdisease was a pri-
mary goal in the design of our preemptive treatment
strategy, a complementary goal was to limit treatment
to patients at highest risk of developing CMV disease.
The probability of any CMV reactivation among R1
patients was 59.0% (95% CI, 54.8-62.9) in the antige-
nemia group and 76.1% (95% CI, 70.9-80.3) in the
PCR group. Among D1/R2 patients, the probability
of any reactivation was 23.4% (95% CI, 16.4-31.1) in
the antigenemia group and 31.7% (95% CI, 21.1-
43.9) in the PCR group (Figure 1A). Among the pa-
tients tested byPCR, the probability of achieving a viral
load .100 copies/mL in the first 100 days after HCT
was 67.0% in the seropositive patients (n5 206 of 307;
95%CI, 61.4-71.9) and 26.7% in the D1/R2 patients
(n 5 16 of 60; 95% CI, 16.3-38.2). The probability of
achieving a viral load .500 copies/mL in the same
time period was 45.9% (n 5 141 of 307; 95% CI,
40.3-51.4) in the R1 patients and 18.3% (n 5 11 of
60; 95% CI, 9.8-29.0) in the D1/R2 patients. Among
the 222 patients who had a viral load.100 copies/mL,
46 (21%) reached the 500 copies/mL threshold on the
same day, and 105 (47%) reached .500 copies/mL at
a median of 7 days (range, 1-63 days) from first reach-
ing .100 copies/mL.For the antigenemia group, any antigenemia was
the treatment threshold, so that time to reactivation
was the same as time to initiation of treatment. In the
PCR group, however, the cumulative incidence of pre-
emptive therapy among seropositive patients was
55.0% (95% CI, 49.3-60.4) and was 25.0% (95% CI,
14.9-36.4) in D1/R2 patients (Table 2). Preemptive
treatment in the PCR group was started at a threshold
level of 100 copies/mL for only 58 patients (15%). The
remaining 126 patients (33%) for whom preemptive
therapy was initiated either had a viral load .500 or
had a 5-fold increase in viral load between 2 consecu-
tive tests. Documented indications for treatment at
lower threshold were steroids.1 mg/kg in 30 patients
(52%), steroids\1 mg/kg in 8 patients (14%), admin-
istration of antithymocyte globulin in 2 patients (3%),
and missing in 18 patients (31%). None of the 31 pa-
tients who had a positive PCR test but never had a viral
load .100 copies/mL received treatment.
The selected risk-adapted CMV PCR treatment
thresholds, although more sensitive, still appropriately
restricted preemptive treatment such that the cumula-
tive incidence of initiating preemptive antiviral ther-
apy in the first 100 days posttransplantation in the
PCR group was not different from that of the antige-
nemia group (HR, 0.95; 95% CI, 0.8-1.1; P 5 .60)
(Figure 1A and B).
Next, we compared the characteristics of the pa-
tients who developed CMV disease despite adherence
to the prevention strategies. In the antigenemia co-
hort, 33 of 41 cases of CMV disease in the first
100 days after HCT (79%) occurred without a positive
screening test (P\ .001). In the risk-adapted PCR co-
hort, only 4 of 19 cases (21%) occurred without a prior
positive test (Table 4). Seven of the 19 cases (37%) in
the PCR group were diagnosed after .4 days of pre-
emptive therapy and all had GI disease. In the PCR
group, there were 8 cases (42%) in which the PCR
was positive at a level below the treatment threshold,
so treatment was started less than 48 hours before
CMV disease was diagnosed. In these cases, the me-
dian time from a first positive PCR test to CMV dis-
ease was 22 days (range, 2-68 days). However, it is
not clear that a lower treatment threshold would
have prevented these cases. For example, patient G5
first showed evidence of CMVDNAemia on day 20 af-
ter HCT, and preemptive therapy was initiated on day
27 for a rising viral load. She completed 1 week of in-
duction therapy followed by 2 weeks of maintenance
therapy. Her screening tests on days 56, 63, and 70
were negative, and she was diagnosed with CMV gas-
tritis on day 76 (Table 4). In fact, if the treatment
threshold were lowered to any level of DNAemia,
only 5 of these 8 patients would have received treat-
ment earlier near the time of their CMV disease diag-
nosis. To lower the treatment threshold to any level of
viral load would have meant treating an additional 67
Table 2. CMV Reactivation and Disease Endpoints Stratified by CMV Serostatus and Surveillance Method
CMV Seropositive (R+) CMV Seronegative (D+/R2)
pp65 Antigen (n 5 566) PCR Viral Load (n 5 322) pp65 Antigen (n 5 124) PCR Viral Load (n 5 62)
Any CMV reactivation by day 100
Cumulative incidence estimate 59.0% 76.1% 23.4% 31.7%
Number of events 334 234 29 19
Median days to reactivation (range) 45 (2-97) 31 (0-97) 52 (31-89) 41 (20-77)
Initiation of preemptive therapy by day 100
Cumulative incidence estimate 59.4% 55.0% 23.3% 25.0%
Number of events 336 169 29 15
Median days to initiation (range) 45 (2-97) 38 (1-94) 52 (31-89) 49 (30-96)
CMV disease by day 100
Cumulative incidence estimate 6.9% 5.6% 0.8% 3.3%
Total number of events 41 17 1 2
Pneumonia 27 4 1 2
GI 14 13 0 0
Median days to disease (range) 47 (0-99) 49 (14-93) 19 (n/a) 76 (56-96)
CMV disease in first year
Cumulative incidence estimate 12.9% 11.5% 2.7% 3.5%
Total number of events 64 30 3 2
Pneumonia 40 12 1 2
GI 24 18 2 0
Median days to disease (range) 89 (0-361) 80 (14-310) 116 (19-151) 76 (56-96)
CMV indicates cytomegalovirus; R+, CMV seropositive recipient; D+/R2, CMV seropositive donor/CMV seronegative recipient; GI, gastrointestinal;
n/a, not applicable.
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cases. If the treatment threshold were lowered to 100
copies/mL for all patients, an additional 33 patients
(9% of patients) would have been treated.
Late CMV disease (after day 100) occurred in 39 of
the 881 patients who survived to day 100 without
CMV disease. As the late CMV prevention strategy
used PCR testing in both cohorts, differences between
the antigenemia and PCR cohorts reflect only changes
over time (early vs late). Although 18 of 26 patients
(69%) in the early group had no PCR surveillance
data within 30 days of their CMV disease, only 3 of
13 patients in the late group had not had surveillance
testing within 30 days of their disease diagnosis. In
the late group, 6 of 13 patients (46%; 4 cases pneumo-
nia, 2 cases GI) had positive surveillance tests (viral
load range, 36-660 copies/mL) before their disease
(median 24 days; range, 7-26 days), but preemptive
treatment was not started because the level was below
the treatment threshold of 1,000 copies/mL. The pro-
portion of late CMVdiseasemanifesting as pneumonia
was similar in the 2 groups (9 of 13, 69% in PCR/late
vs 14 of 26, 54% in antigenemia/early; P 5 .50).Neutropenia
Despite similar rates of antiviral treatment initia-
tion in the 2 CMV surveillance groups, patients
monitored by PCR had a somewhat higher risk of
CMV-related neutropenia (ANC \200/mm3) than
those monitored by antigenemia (cumulative inci-
dence estimate 6.8% vs 4.3%). Adjusting for age, use
of mycophenolate mofetil (MMF) for GVHD prophy-
laxis, CD341 cell dose (above or below the median),and relapse [27], there was a trend toward increased
probability of CMV-related neutropenia (aHR 1.53;
95% CI, 0.9-2.6; P 5 .12) in patients in the PCR sur-
veillance group. The 2 groups were similar in total
days of ganciclovir or days of ganciclovir before this
episode of significant neutropenia. The median days
of ganciclovir use in the antigenemia group with neu-
tropenia was 22 days (range, 9-55 days) compared to
the PCR group of 21 days (range, 5-51 days;
P 5 .64). In an adjusted analysis of the entire study
population including CMV D2/R2 transplantation
recipients, secondary neutropenia, defined as any
ANC\500/mm3 after achieving engraftment and be-
fore day 100, was 2 times more likely to occur in the
later era (2007-2009) than the earlier era (2002-2005)
(HR, 1.96; 95% CI, 1.2-3.2; P\ .01). The cumulative
incidence estimates were 20.9% (95% CI, 18.5-23.4)
in the early time period and 27.2% (95% CI, 23.6-
30.9) in the later period. To evaluate further whether
the apparent increase in neutropenia for the PCR
group was caused by temporal changes in incidence,
we tested the interaction between era and use of sur-
veillance (P 5 .16), indicating that the change in
CMV surveillance strategy from antigenemia to viral
load did not alter the risk of secondary neutropenia
beyond the effects of time. Compared to the D2/R2
patients in the early time period (cumulative incidence
15.0%; 95% CI, 11.4-19.0), the risk of secondary
neutropenia in the antigenemia surveillance group
(cumulative incidence 23.8%; 95% CI, 20.7-27) was
double (aHR, 2.14; 95% CI, 0.9-5.2; P5 .09). In con-
trast, the adjusted hazard of neutropenia in the PCR
surveillance group did not differ in D1/R2 and R1
patients compared with D2/R2 patients (cumulative
Figure 1. (A) Cumulative incidence of cytomegalovirus (CMV) reactivation, (B) initiation of preemptive therapy, (C) CMV disease in seropositive
recipients (R1) and (D) CMV seropositive donor/CMV seronegative recipient (D1/R2) patients (n 5 1,057).
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CI, 17.8-29.2; HR, 1.09; 95% CI, 0.5-2.4; P 5 .82).Invasive Bacterial and Fungal Disease
Next, we aimed to determine whether the trend to-
ward more neutropenia led to more frequent invasive
bacterial and fungal disease. We noted an increased
risk of Gram-negative bacteremia within the first
100 days after HCT in the PCR group (17.4%; 95%
CI, 13.8-21.5) compared to the antigenemia group
(9.3%; 95% CI, 7.3-11.6) (HR, 1.93; 95% CI, 1.4-
2.7; P \ .001). However, an analysis including the
D2/R2 cohort and testing for interaction between
surveillance use and era illustrated that in comparisonto D2/R2 patients within the same era (cumulative
incidence 6.6% earlier vs 11.7% later), the relative
hazards of Gram-negative bacteremia were similar be-
tween those tested with PCR vs antigenemia (P5 .99),
suggesting that the increased risk observed in the PCR
group is confounded by time. The aHR for the antige-
nemia group compared to the D2/R2 patients was
1.47 (95% CI, 0.9-2.4; P 5 .12), and the aHR for the
PCR surveillance group was 1.43 (95% CI, 0.9-2.3;
P5 .14). Furthermore, the cumulative incidence of in-
vasive fungal disease in the first 100 days after HCT
was not significantly different between patients in the
antigenemia group (6.4%; 95% CI, 4.7-8.4) compared
to the PCR group (5.2%; 95% CI, 3.2-7.8) (HR, 0.81;
95% CI, 0.5-1.4; P 5 .45).
Table 3. Risk Factors for CMV Disease by Day 100 and 1-Year Posttransplantation
No. of
Patients Events
CMV Disease Day 100
Events
CMV Disease 1 Year
Univariate Multivariate Univariate Multivariate
HR 95% CI
P
Value aHR* 95% CI
P
Value HR 95% CI
P
Value aHR* 95% CI
P
Value
CMV surveillance
pp65 antigen 690 41 1 67 1
PCR 367 19 0.89 0.5-1.5 .67 1.04 0.6-1.9 .90 32 0.92 0.6-1.4 .69 0.93 0.5-1.7 .80
Age
<40 years 569 20 1 32 1
$40 years 1,028 40 1.04 0.6-1.8 .90 67 1.11 0.7-1.7 .63
Donor age
<40 years 514 30 1 51 1
$40 years 543 30 0.91 0.5-1.5 .72 48 0.86 0.6-1.3 .47
Sex
Male 593 30 1 50 1
Female 464 30 1.32 0.8-2.2 .28 49 1.28 0.9-1.9 .22
Sex matching
Matched 559 28 1 50 1
Female donor/male
recipient
263 18 1.31 0.7-2.4 .38 26 1.07 0.7-1.7 .77
Male donor/female
recipient
235 14 1.19 0.6-2.3 .59 23 1.12 0.7-1.8 .65
Disease risk
Low risk 176 12 1 19 1
Standard risk 506 21 0.65 0.3-1.3 .25 40 0.76 0.4-1.3 .33
High risk 375 27 1.17 0.4-1.7 .67 23 1.18 0.7-2.0 .57
Recipient CMV serostatus
Negative 184 3 1 5 1
Positive 873 57 4.04 1.3-12.9 .02 5.3 1.3-21.7 .02 94 4.23 1.7-10.4 .002 3.92 1.2-12.7 .02
HSV-1 serostatus
Negative 189 10 1 18 1
Positive 866 50 1.22 0.6-2.5 .58 81 1.09 0.7-1.8 .74
Conditioning regimen
Myeloablative with TBI 209 20 1 29 1
Myeloablative without
TBI
471 24 0.49 0.3-0.9 .02 0.62 0.3-1.2 .16 36 0.53 0.3-0.8 .01 0.60 0.3-1.1 .11
Nonmyeloablative 377 16 0.42 0.2-0.8 .01 0.56 0.3-1.2 .13 34 0.58 0.4-1.0 .03 0.80 0.4-1.5 .51
HLA matching
Related/matched 500 23 1 35 1
Unrelated/mismatched 557 37 1.46 0.9-2.4 .16 1.36 0.8-2.3 .25 64 1.71 1.1-2.6 .01 1.34 0.8-2.3 .28
Stem cell source
BM 222 14 1 21 1
Peripheral blood 835 46 0.93 0.5-1.7 .82 78 1.04 0.6-1.7 .88
Posttransplantation
factors
aGVHD
Grade 0-1 480 10 1 16 1
Grade 2 879 36 0.67 0.4-1.2 .19 0.71 0.3-1.6 .39 62 0.77 0.5-1.2 .29
Grade 3-4 218 14 1.73 0.9-3.4 .11 1.4 0.6-3.4 .45 20 1.75 1.0-3.0 .04 1.79 1.1-3.0 .03
cGVHD
No 390 n/a 30 1
Yes 444 39 1.96 1.1-3.6 .03 1.37 0.6-2.9 .41
Missing 223
CMV indicates cytomegalovirus; HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; TBI, total body irradiation; BM, bone marrow;
aGVHD, acute graft-versus-host disease; cGVHD, chronic GVHD; n/a, not applicable.
The numbers in boldface represent associations with significant p-values in either univariate or multivariable analyses.
*Hazard ratios are adjusted for CMV serostatus, conditioning regimen, HLA matching. For posttransplantation risk factors, each factor was added sep-
arately to a model adjusted for CMV serostatus, conditioning regimen, and HLA matching.
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NRM in the first year posttransplantation did not
differ by CMV surveillance method. As depicted in
Figure 2A, cumulative incidence of death without re-
lapse in the antigenemia group was 21.2% (95% CI,
18.4-24.0) at 1 year after HCT, compared with
21.6% (95% CI, 18.9-24.4) in the PCR group(P 5 .14). In multivariable models, pretransplantation
risk factors significantly associated with NRM in this
cohort were patient age .40 years, high-risk underly-
ing disease, and mismatched or unrelated HLA (data
not shown). CMV serostatus was not associated with
increased NRM among the cohort at risk (R1 vs
D1/R2). When comparing to the D2/R2 cohort,
Table 4. Characteristics of CMV Disease Cases Occurring within the First 100 Days after HCT during PCR Era
GI
Disease Disease
CMV
Status
Day*
First
Test
Day*
First
PCR +
Viral Load
(Copies/mL)
First PCR +
Day* Rx
Start
Day* CMV
Disease
Days from Rx
Start to
CMV Disease Comments
Case
G1† MDS + 26 – – – 41 –
G2† CMML 2 6 – – – 56 –
G3† MM + 4 27 330 – 20 –
G4‡ ALL + 6 12 34 – 66 – PCR day 54 160 copies/mL, negative days 60 and 69
G5‡ AMOL + 6 20 82 27 76 – PCR-negative days 56-77
G6‡ Other + 8 15 34 – 83 – PCR-negative days 22-75
G7‡ MM 2 5 75 160 – 97 – Persistent DNAemia (68-250 copies/mL) from day 75
G8‡ AMOL + 16 16 83 19 21 2
G9 ALL + 20 41 6700 41 46 5 PCR-negative days 20-34
G10 AMML + 21 35 94 46 55 9 PCR-negative days 21-28
G11 MM + 28 83 140 83 93 10 PCR-negative days 28-76
G12 MDS + 12 38 1700 38 49 11 PCR-negative day 27, next test delayed
G13 AML + 0 26 300 29 43 14
G14 AMML + 19 47 260 51 69 18
G15 CLL + 19 30 57 39 62 23
Pneumonia
Case
P1† AML + 11 19 26 – 14 – Concomitant fungal pneumonia prompted BAL
P2‡ NHL + 11 41 56 – 56 – PCR-negative day 48, CMV diagnosed at autopsy
P3‡ ALL + 17 17 100,000 17 19 2 First test delayed
P4‡ CML + 12 18 67 21 22 1
CMV indicates cytomegalovirus; HCT, hematopoietic cell transplantation; GI, gastrointestinal; +, positive; Rx start, preemptive therapy start day; MDS,
myelodysplastic syndrome; CMML, chronic myelomonocytic leukemia; 2, negative; MM, multiple myeloma; ALL, acute lymphocytic leukemia; AMOL,
acute monocytic leukemia; Other, Waldenstrom macroglobulinemia; AMML, acute monomyelocytic leukemia; AML, acute myeloid leukemia; CLL,
chronic lymphocytic leukemia; BAL, bronchoalveolar lavage; NHL, non-Hodgkin lymphoma; CML, chronic myeloid leukemia.
*All days are in reference to date of HCT (day 0).
†No positive screening test before CMV disease diagnosis.
‡Preemptive therapy not initiated before CMV disease diagnosis or initiated within 48 hours of diagnosis.
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group (P \ .05) but not in D1/R2 or D1/R1
(Table 5, Figure 2B).
After adjusting for age, disease risk, and HLA
matching, posttransplantation events associated with
NRM were grades 3 to 4 aGVHD and several CMV-
related outcomes. Detection of any CMV reactivation,
at any level by either method, was associated with
a 61% increase in the probability of death without re-
lapse, and reactivation to levels above the treatment
threshold was associated with an 84% increased prob-
ability. Controlling for neutropenia occurring after
antiviral initiation diminishes the effect (aHR, 1.34;
P 5 .09), indicating that this increased risk of NRM
may be mediated by treatment-related neutropenia.
Finally, CMV end organ disease was associated with
a 4-fold increased probability of death, most of this at-
tributable to CMV pneumonitis because GI disease
was not associated with death (Table 5).
Overall mortality was also not different between
the 2 surveillance groups after adjusting for age, dis-
ease risk, and HLA matching (aHR, 1.10; 95% CI,
0.9-1.4; P 5 .37).DISCUSSION
In this prospective study of a large HCT cohort,
we describe the successful transition from a CMV sur-veillance strategy using pp65 antigenemia testing to
one using a quantitative PCR test with treatment
thresholds determined based on patient risk factors.
Our goal was to devise a prevention strategy that
would be able to identify and treat patients at highest
risk of rapid CMV replication without increasing the
proportion of patients receiving preemptive therapy
and potentially exposing more patients to unnecessary
toxicity. We observed no increase in initiation of pre-
emptive therapy during the first 100 days after HCT
with the CMV PCR testing and risk-adapted thresh-
olds. In both surveillance groups, preemptive therapy
was started in approximately 55% of the seropositive
patients and 25% of the seronegative patients. Fur-
thermore, the incidence of CMV disease was similar
between the surveillance groups with cumulative inci-
dence estimates of 12% in R1 patients and 3% in
D1/R2 patients by 1 year after HCT. These esti-
mates, in general, are in agreement with other recent
studies of CMV infection and disease after allogeneic
HCT [28-31].
Interestingly, we found a trend toward decreased
incidence of CMV pneumonia and increased incidence
of GI disease. Although these differences did not reach
statistical significance, given the strong association be-
tween CMV pneumonitis and mortality, these trends
may become clinically relevant. Few other studies re-
port organ-specific CMV incidence rates during this
Figure 2. Cumulative incidence of nonrelapse mortality (NRM) by
1 year after hematopoietic cell transplantation (HCT). (A) Cytomegalo-
virus (CMV) surveillance group (n 5 1,057). (B) Donor and recipient
CMV serostatus (n 5 1,597).
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ing allogeneic transplantations after reduced-intensity
conditioning, Pi~nana et al. [29] also describe a lower
incidence of CMV pneumonia among patients fol-
lowed by PCR surveillance than by antigenemia. The
fact that CMVGI disease was not associated with over-
all mortality is noteworthy, as it further supports that
this manifestation of CMV disease is more amenable
to treatment with antiviral therapy.
An important question to address is why we did not
observe a reduction in GI CMV disease in the PCR
surveillance group. Our data seem to suggest that, un-
like lung disease, CMV viral load in plasma does not
adequately represent CMV replication in the GI mu-
cosa in some patients. Nearly half of the GI disease
cases occurred after the patient had been receiving
induction therapy for at least 2 days, indicating
that treatment did not sufficiently halt replication to
prevent disease or that replication in tissue had already
started significantly earlier.
Late CMV disease continues to occur in approxi-
mately 4% of patients who survive to day 100. That
46% of late disease occurred among patients who
had multiple positive PCR tests just before their diag-
nosis raises the question whether a lower threshold
might be more effective in preventing late disease.This is especially concerning, as more than half of
late CMV disease cases are still pneumonia [32].
The PCR surveillance strategy was associated with
a trend toward increased probability of CMV-related
neutropenia and Gram-negative bacteremia, but the
analysis suggests that the observed associations are
confounded with time and may not be causally related
to use of the PCR surveillance strategy. There was no
association between use of PCR surveillance and in-
creased risk of invasive fungal disease. A detailed exam-
ination of these findings was beyond the scope of this
article but certainly calls for future exploration. In
a prior analysis, we noted a 50% increase in the rate
of Gram-negative bacteremia in the first 100 days after
allogeneic HCT as we transitioned from ceftazidime
to levofloxacin for prophylaxis during neutropenia
(2000-2002 vs 2002-2005) [33].Other groups have re-
ported an increasing risk of Gram-negative bacter-
emias after HCT associated with levofloxacin
prophylaxis [34].
This study also suggested an association of pre-
emptive therapy on NRM. The association was dim-
inished when we controlled for posttreatment
neutropenia, but a statistical trend continued. CMV
donor and recipient pretransplantation serostatus was
significantly associated with NRM at 1 year only
among D2/R1 patients. We speculate that this may
be due to improved prevention of fatal CMV disease,
treatment-related toxicities, and perhaps improved
management of the indirect effects of CMV infection
including invasive fungal disease [35,36]. Because the
current cohort is relatively restricted—umbilical cord
blood and ex vivo T cell-depleted transplantations
were not included—confirmation of this finding in
other contemporary cohorts is needed.
Our study was limited by the observational design.
We recognize that a randomized clinical trial compar-
ing the 2 prevention strategies would have eliminated
the problem of confounding with changing patterns
over time. However, by adding the D2/R2 cohort,
we were able to test for interaction between the surveil-
lance method and time, and the large sample size and
the uniformprevention strategy in each time period per-
mitted us to perform multivariable modeling that likely
accounted for possible confounders. Overall adherence
to the risk-adapted preemptive treatment guidelines
was good. The most common deviation from the rec-
ommendations was treatment at a lower threshold value
for patients receiving\1 mg/kg of steroids.
The strategy evaluated here is the first that
systematically combines quantitative plasmaCMV test-
ing with an ultrasensitive plasma PCR assay and in vivo
replication dynamics to maximize early detection on
the one hand and specificity on the other hand. Al-
though such levels of sensitivity are not uniformly
reached with contemporary commercial assays, newer
assays that can reliably detect CMV DNA levels to
Table 5. CMV-Related Risk Factors for NRM by 1 Year Posttransplantation (n 5 1,057)
No. of
Patients Events HR
Univariate
95% CI P Value aHR*
Multivariate
95% CI P Value
CMV surveillance
pp65 antigen 690 144 1
PCR 367 75 1.0 0.81.3 1 1.03 0.8-1.4 .84
CMV serostatus
D+/R2 184 33 1
R+ 873 186 1.21 0.8-1.7 .32
CMV serostatus†
D2/R2 540 94 1 1
D+/R2 184 33 1.04 0.7-1.5 .84 1.09 0.7-1.6 .66
D2/R+ 440 102 1.38 1.0-1.8 .02 1.33 1.0-1.8 .05
D+/R+ 433 84 1.13 0.8-1.5 .40 1.15 0.9-1.6 .35
CMV serostatus†
D2/R2 540 94 1 1
D+/R2 184 33 1.04 0.7-1.5 .83 1.09 0.7-1.6 .65
R+ 873 186 1.26 1.0-1.6 .07 1.25 1.0-1.6 .09
Posttransplantation risk factors‡
CMV disease
No 972 186 1
Yes 85 33 4.41 2.9-6.8 <.001 4.16 2.7-6.5 <.001
CMV GI disease
No 1018 213 1
Yes 39 6 1.15 0.5-2 7 .75 1.19 0.5-2.8 .69
CMV pneumonia
No 1010 191 1
Yes 47 27 8.76 5.2-14.6 <.001 8.18 4.8-13.8 <.001
Any CMV reactivation
No 442 90 1
Yes 615 129 1.65 1.2-2.2 .001 1.61 1.2-2.2 .002
CMV reactivation triggering preemptive therapy
No 509 99 1
Yes 548 120 1.84 1.4-2.5 <.001 1.76 1.3-2.4 <.001
CMV reactivation triggering preemptive therapy, also controlling for
posttreatment neutropenia
1.34 1.0-1.9 .09
CMV indicates cytomegalovirus; NRM, nonrelapse mortality; HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; D+/R2, CMV sero-
positive donor/CMV seronegative recipient; R+, CMV seropositive recipient; D2/R2, CMV seronegative donor/CMV seronegative recipient; D2/R+,
CMV seronegative donor/CMV seropositive recipient; D+/R+, CMV seropositive donor/CMV seropositive recipient; GI, gastrointestinal.
The numbers in boldface represent associations with significant p-values.
*Hazard ratios are adjusted for age, disease risk, and HLA matching.
†Analysis includes original cohort plus 540 D2/R2 patients.
‡All posttransplantation risk factors were individually added into a model adjusted for age, disease risk, and HLA matching.
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Also, the availability of an international standard for
CMV assay calibration will make it possible to make
clearer interinstitutional comparisons [39].
In conclusion, the adoption of a viral load-based
risk-adapted preemptive strategy for the prevention
of CMV in a large allogeneic HCT cohort resulted
in similar rates of CMV disease and NRM without
an increase in the proportion of patients receiving pre-
emptive therapy or an attributable increase in the risk
of ganciclovir-related toxicities. Setting a lower treat-
ment threshold in patients at greater risk of rapid
CMV replication, such as patients receiving high-
dose steroids or anti-T cell therapies, targeted pre-
emptive treatment to those at greatest risk. Although
CMV GI disease continues to occur in the absence
of DNAemia, antiviral treatment is generally effective,
and there is no association with mortality. In contrast,
PCR-based preemptive therapy effectively prevented
CMV pneumonia, yet the few cases that did occur
continued to be associated with extremely poor out-comes. Whether further lowering the threshold for
preemptive therapy would be beneficial cannot be de-
termined from this study. Our projections suggest that
about 20% to 25% of the breakthrough cases could
potentially have been prevented but at the expense
of treating substantially more patients. The next truly
innovative step forward in CMV prevention will prob-
ably only come with the availability of drugs with an
improved safety profile that can be given either pro-
phylactically or to a larger proportion of patients
based on lower PCR levels or vaccines [40].ACKNOWLEDGMENTS
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